89bio reports second quarter 2022 financial results and provides corporate update

- reported positive topline results from entrigue phase 2 trial of pegozafermin in severe hypertriglyceridemia patients; initiation of phase 3 trial expected in the first half of 2023 -

ETNB Ratings Summary

ETNB Quant Ranking